Please login to the form below

Not currently logged in
Email:
Password:

reimbursement models

This page shows the latest reimbursement models news and features for those working in and with pharma, biotech and healthcare.

The business case for patient engagement

The business case for patient engagement

b)  Reimbursement models are evolving. Until recently, reimbursement was rather indirect, for example, by using digital medicines for safeguarding pay-for-performance deals and value-based reimbursement models. ... The next step is direct reimbursement

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    and Scandinavia. Each of the different models are variations of a fee-for-service reimbursement model, which have evolved to meet the needs of chronic illnesses. ... Incremental changes may work in the short-term. Incremental changes include solutions

  • Lighting the way Lighting the way

    This pathway would better align the current regulatory, reimbursement, evaluation and diffusion processes, and provide companies with tailored support in navigating the new, simplified system. ... reimbursement models” for greater patient access.

  • Market access improvements in Turkey Market access improvements in Turkey

    In 2015 there were 8, 104 products on the reimbursement list, with 292 new ones added. ... company. Alternative reimbursement models. The SGK was first authorised in September 2014 to develop 'alternative reimbursement models' as a new channel through

  • Managing real world data governance Managing real world data governance

    These emerging regulatory and reimbursement models all aim to make treatment provision and access more sensitive to the evolving evidence base, and all require RWD. ... models. Where the appropriate safeguards are in place, authorisation should be based

  • Turkey: A growing pharma market with huge potential Turkey: A growing pharma market with huge potential

    With the recent enactment of Law 6552, the Social Security Institution has been authorised to develop alternative reimbursement models. ... Although these alternative reimbursement models can provide a way out, without objective reimbursement

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics